Current disease status-Recurrent cancer Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

Searching for patients with unresponsive breast cancer to trial an experimental treatment.

Searching for patients with unresponsive breast cancer to trial an experimental treatment.

Posted by on Aug 15, 2021 in Breast cancer | 0 comments

In a nutshell This trial aims to assess the safety and effectiveness of an experimental drug, CYT-0851 in the treatment of B-cell and solid tumors, including breast cancer, that have come back or are no longer responsive to treatments. The main outcomes to be measured are the side effects and the overall response to the treatment....

Read More

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Looking for patients with HER-2 positive advanced breast cancer to trial an experimental treatment.

Posted by on Jan 28, 2021 in Breast cancer | 0 comments

In a nutshell This trial is aiming to examine the safety and effectiveness of an experimental treatment called BPX-063, a CAR-T cell treatment, in patients with advanced HER-2 positive breast cancer. The main outcomes to be measured are the maximum tolerated dose of BPX-603 and the antitumor activity. This trial is being carried out across the...

Read More

Evaluating belotecan as an alternative treatment for topotecan for sensitive-relapsed small-cell lung cancer.

Evaluating belotecan as an alternative treatment for topotecan for sensitive-relapsed small-cell lung cancer.

Posted by on Dec 29, 2020 in Lung cancer | 0 comments

In a nutshell This study looked at the effectiveness and safety of belotecan (Bel; Camtobell) and topotecan (Top; Hycamtin) as therapy for sensitive relapsed small-cell lung cancer (SCLC). The authors found that Bel could be used as an alternative to Top for sensitive-relapsed SCLC.  Some background SCLC...

Read More

Searching for patients with advanced non-small cell lung cancer to trial a radiation treatment

Searching for patients with advanced non-small cell lung cancer to trial a radiation treatment

Posted by on Nov 8, 2020 in Lung cancer | 0 comments

In a nutshell This trial is looking at the effectiveness of Quad Shot (QS) radiation therapy (RT) to relieve symptoms in patients with advanced non-small-cell lung cancer (NSCLC). The main outcome that is to be measured is the occurrence of side effects over the course of 3-months. This trial is being carried out in New Jersey and New York,...

Read More

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Longer-term outcomes for olaparib in the treatment of advanced castration-resistant prostate cancer

Posted by on Oct 24, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated longer-term survival rates and the safety of olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC). It found that treatment with olaparib led to significantly longer survival, especially in men with gene alterations. Some background CRPC is an especially aggressive...

Read More

Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.

Osimertinib in EGFR-positive non-small cell lung cancer spread to the brain or the layers surrounding the brain.

Posted by on Oct 24, 2020 in Lung cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of osimertinib (Tagrisso) in non-small cell lung cancer (NSCLC) that has spread to the brain of the layers of the brain (meninges). The authors concluded that osimertinib showed improved survival and had a good response rate in these patients. Some...

Read More

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Quality of life in patients with metastatic prostate cancer under cabazitaxel treatment

Posted by on Oct 10, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...

Read More

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

Comparing regorafenib plus chemotherapy to other biological drugs for the second-line treatment of metastatic colorectal cancer

Posted by on Sep 30, 2020 in Colorectal cancer | 0 comments

In a nutshell This analysis was carried out to look at including regorafenib (Stivarga) in second-line therapy for patients with metastatic colorectal cancer (mCRC). The authors found that regorafenib in combination with chemotherapy might be an alternative to standard second-line treatment options for these patients. Some...

Read More

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...

Read More

Does durvalumab with or without tremelimumab offer potential as a third line or later treatment of advanced non-small-cell lung cancer?

Does durvalumab with or without tremelimumab offer potential as a third line or later treatment of advanced non-small-cell lung cancer?

Posted by on Jul 12, 2020 in Lung cancer | 0 comments

In a nutshell This study assessed whether patients with metastatic non-small-cell lung cancer (mNSCLC) would benefit from treatment using durvalumab (Imfinzi) with or without tremelimumab (CP-675,206) as a later treatment. The authors concluded that durvalumab showed improvement in overall survival (OS) and...

Read More